New Ways to Treat HIV Infection
Targeted Degradation of HIV Integrase as a Novel Treatment of Infection
['FUNDING_R21'] · XAVIER UNIVERSITY OF LOUISIANA · NIH-11161606
This project looks for new ways to treat HIV infection, especially for people whose current medications are no longer working well.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | XAVIER UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-11161606 on ClinicalTrials.gov |
What this research studies
HIV infection is now a treatable condition, but some people are developing resistance to existing medications. This project aims to create a new type of medicine called PROTACs, which work differently than current drugs. Instead of just blocking the virus, PROTACs are designed to destroy specific viral proteins, like HIV integrase, that the virus needs to survive. This new approach could offer a powerful way to overcome drug resistance and provide more effective treatment options.
Who could benefit from this research
Good fit: Patients who have HIV infection, particularly those experiencing drug resistance to current antiretroviral therapies, are the target beneficiaries of this research.
Not a fit: Patients without HIV infection or those whose current HIV treatments are fully effective may not directly benefit from this specific new drug development.
Why it matters
Potential benefit: If successful, this approach could lead to new medications that are effective against drug-resistant HIV, offering hope for patients who currently have limited treatment options.
How similar studies have performed: While PROTAC technology is a newer approach in drug development, similar strategies for degrading proteins have shown promise in other disease areas, making this a novel application for HIV.
Where this research is happening
NEW ORLEANS, UNITED STATES
- XAVIER UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, GUANGDI — XAVIER UNIVERSITY OF LOUISIANA
- Study coordinator: WANG, GUANGDI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus